Unichem Laboratories Limited's Board of Directors approved the unaudited financial results (consolidated and standalone) for the quarter ended 31st March 2025, and the audited financial statements (consolidated and standalone) for the year ended 31st March 2025.
Re-appointed M/s. Kishore Bhatia & Associates as Cost Auditors for FY 2025-26.
Appointed M/s. Alwyn Jay & Co. as Secretarial Auditors for five years from FY 2025-26 to 2029-30, subject to members' approval.
Re-appointed M/s. Ram Agarwal & Associates as Internal Auditor for FY 2025-26.
Amended Code of Practices and Procedures for Fair Disclosure of UPSI as per SEBI regulations.
Consolidated revenue from operations for the quarter ended 31st March 2025 stood at ₹587.18 crore, and ₹2,110.97 crore for the year ended 31st March 2025.
Consolidated profit after tax for the quarter ended 31st March 2025 was ₹52.97 crore, and ₹137.52 crore for the year.
Standalone revenue from operations for the quarter ended 31st March 2025 was ₹461.24 crore, and ₹1,735.70 crore for the year.
Standalone profit after tax for the quarter ended 31st March 2025 was ₹51.22 crore, and ₹162.96 crore for the year.
During the year ended 31st March 2025, Unichem and its subsidiary Unichem Pharmaceutical (USA), Inc. entered into an agreement with Bayshore Pharmaceuticals LLC, USA for the purchase of rights, title and interest in product approvals and the USA generics formulations marketing/distribution business.
The company announced its intention to close the manufacturing facility of its wholly owned subsidiary Niche Generics Limited.
Subsequent to the year ended 31st March 2025, the Company has transferred its 100% stake in its wholly owned subsidiary Unichem Laboratories Limited, Ireland to Company's holding company , Ipca Laboratories Limited for a consideration of ₹4.00 crores.